Two of Canada’s leading patient groups, the Gastrointestinal Society and the Canadian Society of Intestinal Research, are calling on patients with inflammatory bowel disease (IBD) to participate in a survey to help identify what’s missing in their care. They are also asking Canadian patients with any inflammatory condition who take biologic/biosimilar medication to provide their opinions.

Inflammatory bowel disease

The first survey, IBD Patients: What’s Missing in Your Care?, seeks to learn more about IBD patients’ experiences and their outlook in current management. The survey, available in English and French, follows a similar questionnaire conducted in 2018, but this time is open to IBD patients worldwide in order to collect a larger and more diverse body of information about the IBD patient community. Participants must have been diagnosed with any type of IBD (Crohn disease, ulcerative colitis, ulcerative proctitis, microscopic colitis, etc.). Visit https://badgut.org/ibd-survey-2019 to learn more and participate in the study.

Use of biologic/biosimilar medications for inflammatory diseases

The second survey, the Canadian Biosimilar Medication Experience, explores the experiences and outlook of Canadian patients who use biologic/biosimilar medications to treat inflammatory bowel disease (Crohn disease or ulcerative colitis), as well as other inflammation-causing diseases such as diabetes, rheumatoid arthritis, cancer, osteoporosis, psoriasis, HIV, multiple sclerosis, or growth deficiencies. This survey follows up on one conducted in 2015. Visit https://badgut.org/biosimilars-survey-2019 to learn more and participate in the study.

Data gathered from both surveys will be used anonymously and in aggregate to shape future programming and to inform discussions with community members, health care professionals, and health policy decision-makers.

For more information about the Gastrointestinal Society and the Canadian Society of Intestinal Research visit www.badgut.org.